[
  {
    "ts": "2025-10-16T21:22:31+00:00",
    "headline": "Novo Nordisk, Eli Lilly slide after Trump comments on weight loss drug pricing",
    "summary": "Investing.com -- Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY) shares fell more than 4% each in premarket trading on Friday following comments from President Trump a day earlier regarding potential price reductions for popular weight loss medications.",
    "url": "https://finance.yahoo.com/news/novo-nordisk-eli-lilly-fall-212231851.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "ce6e6bc5-3516-3f57-98eb-b43ba5d5f5c2",
      "content": {
        "id": "ce6e6bc5-3516-3f57-98eb-b43ba5d5f5c2",
        "contentType": "STORY",
        "title": "Novo Nordisk, Eli Lilly slide after Trump comments on weight loss drug pricing",
        "description": "",
        "summary": "Investing.com -- Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY) shares fell more than 4% each in premarket trading on Friday following comments from President Trump a day earlier regarding potential price reductions for popular weight loss medications.",
        "pubDate": "2025-10-16T21:22:31Z",
        "displayTime": "2025-10-16T21:22:31Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-eli-lilly-fall-212231851.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-eli-lilly-fall-212231851.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-16T19:37:28+00:00",
    "headline": "Johnson & Johnson’s (JNJ) Stock Is Now Positioned To “Challenge Eli Lilly,” Says Jim Cramer",
    "summary": "We recently published Jim Cramer Talked About These 8 Stocks & The Quantum Computing Dip. Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed. Johnson & Johnson (NYSE:JNJ) announced yesterday that it would spin off its orthopedics business to allow it to become the largest firm of its kind in the […]",
    "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-stock-now-193728098.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "a7886cdd-3a04-3230-b7b1-fb1b2a9af2e6",
      "content": {
        "id": "a7886cdd-3a04-3230-b7b1-fb1b2a9af2e6",
        "contentType": "STORY",
        "title": "Johnson & Johnson’s (JNJ) Stock Is Now Positioned To “Challenge Eli Lilly,” Says Jim Cramer",
        "description": "",
        "summary": "We recently published Jim Cramer Talked About These 8 Stocks & The Quantum Computing Dip. Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed. Johnson & Johnson (NYSE:JNJ) announced yesterday that it would spin off its orthopedics business to allow it to become the largest firm of its kind in the […]",
        "pubDate": "2025-10-16T19:37:28Z",
        "displayTime": "2025-10-16T19:37:28Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/5ebeb797976f4b134f89e7fc0f1f7cd5",
          "originalWidth": 848,
          "originalHeight": 565,
          "caption": "Johnson & Johnson's (JNJ) Stock Is Now Positioned To \"Challenge Eli Lilly,\" Says Jim Cramer",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qjhajy_X8xr_FpnwS8Zrgg--~B/aD01NjU7dz04NDg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/5ebeb797976f4b134f89e7fc0f1f7cd5.cf.webp",
              "width": 848,
              "height": 565,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5LsSqgRtcwqY7UZvRa9m3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/5ebeb797976f4b134f89e7fc0f1f7cd5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-stock-now-193728098.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-stock-now-193728098.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "KVUE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-16T19:15:06+00:00",
    "headline": "A Look at Eli Lilly’s Valuation Following Landmark Orforglipron Phase 3 Results",
    "summary": "Eli Lilly (LLY) just reported that its investigational pill, orforglipron, achieved every main and secondary goal in two late-stage clinical trials for type 2 diabetes. The data showed better blood sugar control, meaningful weight loss, and cardiovascular improvements compared to both a rival medicine and placebo. See our latest analysis for Eli Lilly. These latest breakthrough trial results have kept the momentum building for Eli Lilly after a year packed with milestones. From the launch of...",
    "url": "https://finance.yahoo.com/news/look-eli-lilly-valuation-following-191506567.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "e0ada195-8ea5-36e4-b02f-b31d6b647ed7",
      "content": {
        "id": "e0ada195-8ea5-36e4-b02f-b31d6b647ed7",
        "contentType": "STORY",
        "title": "A Look at Eli Lilly’s Valuation Following Landmark Orforglipron Phase 3 Results",
        "description": "",
        "summary": "Eli Lilly (LLY) just reported that its investigational pill, orforglipron, achieved every main and secondary goal in two late-stage clinical trials for type 2 diabetes. The data showed better blood sugar control, meaningful weight loss, and cardiovascular improvements compared to both a rival medicine and placebo. See our latest analysis for Eli Lilly. These latest breakthrough trial results have kept the momentum building for Eli Lilly after a year packed with milestones. From the launch of...",
        "pubDate": "2025-10-16T19:15:06Z",
        "displayTime": "2025-10-16T19:15:06Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/look-eli-lilly-valuation-following-191506567.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/look-eli-lilly-valuation-following-191506567.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-16T17:55:00+00:00",
    "headline": "LLY's Oral GLP-1 Pill Scores Another Pair of Diabetes Wins",
    "summary": "Eli Lilly's oral GLP-1 pill orforglipron delivers strong A1C reductions in two late-stage diabetes studies, reinforcing its 2026 filing plans.",
    "url": "https://finance.yahoo.com/news/llys-oral-glp-1-pill-175500565.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "48413277-56a8-373d-821e-5a3ced07ff9a",
      "content": {
        "id": "48413277-56a8-373d-821e-5a3ced07ff9a",
        "contentType": "STORY",
        "title": "LLY's Oral GLP-1 Pill Scores Another Pair of Diabetes Wins",
        "description": "",
        "summary": "Eli Lilly's oral GLP-1 pill orforglipron delivers strong A1C reductions in two late-stage diabetes studies, reinforcing its 2026 filing plans.",
        "pubDate": "2025-10-16T17:55:00Z",
        "displayTime": "2025-10-16T17:55:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MjuR.4zEKm0FgKsxK.lBKQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G.VCDKzJSEg_sv.1sSAJrQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/llys-oral-glp-1-pill-175500565.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/llys-oral-glp-1-pill-175500565.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-16T15:10:00+00:00",
    "headline": "NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio",
    "summary": "Novo Nordisk's $2.1 billion deal for Omeros' zaltenibart aims to strengthen its rare disease pipeline amid GLP-1 market headwinds.",
    "url": "https://finance.yahoo.com/news/nvo-omer-ink-2-1b-151000527.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "d00cbd74-f5a7-3563-9610-4f4dbd0ac732",
      "content": {
        "id": "d00cbd74-f5a7-3563-9610-4f4dbd0ac732",
        "contentType": "STORY",
        "title": "NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio",
        "description": "",
        "summary": "Novo Nordisk's $2.1 billion deal for Omeros' zaltenibart aims to strengthen its rare disease pipeline amid GLP-1 market headwinds.",
        "pubDate": "2025-10-16T15:10:00Z",
        "displayTime": "2025-10-16T15:10:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OpV4giEb4QjgN71LPYFzIw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QcLiFahMpkHBfBp4mOYpEQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/nvo-omer-ink-2-1b-151000527.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/nvo-omer-ink-2-1b-151000527.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "OMER"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-16T14:00:00+00:00",
    "headline": "Lilly confirms date and conference call for third-quarter 2025 financial results announcement",
    "summary": "Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2025 financial results on October 30, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.",
    "url": "https://finance.yahoo.com/news/lilly-confirms-date-conference-call-140000777.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "2951daf1-f6cb-3fd1-8a92-081cd9934ea8",
      "content": {
        "id": "2951daf1-f6cb-3fd1-8a92-081cd9934ea8",
        "contentType": "STORY",
        "title": "Lilly confirms date and conference call for third-quarter 2025 financial results announcement",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2025 financial results on October 30, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.",
        "pubDate": "2025-10-16T14:00:00Z",
        "displayTime": "2025-10-16T14:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
          "originalWidth": 400,
          "originalHeight": 219,
          "caption": "Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Y1fhfHoGbpYMTG8q90VAg--~B/aD0yMTk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 400,
              "height": 219,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Goic7S8PJ1_UseTWpNhHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-confirms-date-conference-call-140000777.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-confirms-date-conference-call-140000777.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-16T13:48:00+00:00",
    "headline": "2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades",
    "summary": "These companies are investing heavily into their pipelines and the payoff for long-term investors can be substantial.",
    "url": "https://www.fool.com/investing/2025/10/16/2-pharmaceutical-growth-stocks-to-buy-now-and-hold/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "e99d6e7f-96ab-30f8-8f78-b81dd92215f1",
      "content": {
        "id": "e99d6e7f-96ab-30f8-8f78-b81dd92215f1",
        "contentType": "STORY",
        "title": "2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades",
        "description": "",
        "summary": "These companies are investing heavily into their pipelines and the payoff for long-term investors can be substantial.",
        "pubDate": "2025-10-16T13:48:00Z",
        "displayTime": "2025-10-16T13:48:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/ca28b85f2cbd868e11377bf14e3a4e6e",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "A patient undergoing a checkup at a doctor's office.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G0C0iXQujr9dNKLNHPUMHQ--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/ca28b85f2cbd868e11377bf14e3a4e6e.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jjv3KCf3XGpgQ.htFEahOw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/ca28b85f2cbd868e11377bf14e3a4e6e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/10/16/2-pharmaceutical-growth-stocks-to-buy-now-and-hold/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-pharmaceutical-growth-stocks-buy-134800014.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AZN.L"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-16T13:31:00+00:00",
    "headline": "How Will Mounjaro and Zepbound Sales Aid Lilly's Upcoming Q3 Results?",
    "summary": "Strong demand for Mounjaro and Zepbound is expected to power LLY's Q3 growth, as both drugs deepen U.S. and global market reach.",
    "url": "https://finance.yahoo.com/news/mounjaro-zepbound-sales-aid-lillys-133100704.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "dd1608f3-bb29-3a19-822c-2a3ddafde65f",
      "content": {
        "id": "dd1608f3-bb29-3a19-822c-2a3ddafde65f",
        "contentType": "STORY",
        "title": "How Will Mounjaro and Zepbound Sales Aid Lilly's Upcoming Q3 Results?",
        "description": "",
        "summary": "Strong demand for Mounjaro and Zepbound is expected to power LLY's Q3 growth, as both drugs deepen U.S. and global market reach.",
        "pubDate": "2025-10-16T13:31:00Z",
        "displayTime": "2025-10-16T13:31:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MjuR.4zEKm0FgKsxK.lBKQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G.VCDKzJSEg_sv.1sSAJrQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/mounjaro-zepbound-sales-aid-lillys-133100704.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/mounjaro-zepbound-sales-aid-lillys-133100704.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-16T11:51:55+00:00",
    "headline": "Here's What to Expect From Eli Lilly’s Next Earnings Report",
    "summary": "What should investors expect from pharma giant Eli Lilly’s upcoming Q3 results?",
    "url": "https://www.barchart.com/story/news/35492078/here-s-what-to-expect-from-eli-lillys-next-earnings-report",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "97914f1b-34d5-3226-8bbc-ca4814bf1193",
      "content": {
        "id": "97914f1b-34d5-3226-8bbc-ca4814bf1193",
        "contentType": "STORY",
        "title": "Here's What to Expect From Eli Lilly’s Next Earnings Report",
        "description": "",
        "summary": "What should investors expect from pharma giant Eli Lilly’s upcoming Q3 results?",
        "pubDate": "2025-10-16T11:51:55Z",
        "displayTime": "2025-10-16T11:51:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/3eb006d76a84a0a4b0ebac5f8867f9c6",
          "originalWidth": 1600,
          "originalHeight": 1067,
          "caption": "Eli Lilly & Co_ by Tada Images via Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ORmCiaC7fQ4pnNEnWgm3oQ--~B/aD0xMDY3O3c9MTYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/barchart_com_477/3eb006d76a84a0a4b0ebac5f8867f9c6.cf.webp",
              "width": 1600,
              "height": 1067,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/C3HoxXjqH6nltkp.0HDWtQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/3eb006d76a84a0a4b0ebac5f8867f9c6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/35492078/here-s-what-to-expect-from-eli-lillys-next-earnings-report",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-expect-eli-lilly-next-115155262.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-16T11:45:00+00:00",
    "headline": "Did Viking Therapeutics Just Say \"Checkmate\" to Eli Lilly?",
    "summary": "The smaller drugmaker is looking to disrupt a fast-growing market.",
    "url": "https://www.fool.com/investing/2025/10/16/did-viking-therapeutics-just-say-checkmate-to-eli/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "ca3e2ae2-dd91-33b9-bdcd-5768a21e4614",
      "content": {
        "id": "ca3e2ae2-dd91-33b9-bdcd-5768a21e4614",
        "contentType": "STORY",
        "title": "Did Viking Therapeutics Just Say \"Checkmate\" to Eli Lilly?",
        "description": "",
        "summary": "The smaller drugmaker is looking to disrupt a fast-growing market.",
        "pubDate": "2025-10-16T11:45:00Z",
        "displayTime": "2025-10-16T11:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/247f4cce999192bb2ed04583d51badf9",
          "originalWidth": 1400,
          "originalHeight": 934,
          "caption": "Patient self-administering a shot.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SfMakwaHFcKv3ztCdlvaCQ--~B/aD05MzQ7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/247f4cce999192bb2ed04583d51badf9.cf.webp",
              "width": 1400,
              "height": 934,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QZ8MLWLvC4vd4fLOrLHKlw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/247f4cce999192bb2ed04583d51badf9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/10/16/did-viking-therapeutics-just-say-checkmate-to-eli/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/did-viking-therapeutics-just-checkmate-114500698.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-16T11:01:31+00:00",
    "headline": "Eli Lilly’s oral GLP-1RA gains fourth Phase III type 2 diabetes win",
    "summary": "The company has announced positive data from the ACHIEVE-2 and ACHIEVE-5 trials, with both meeting all their primary and key secondary endpoints.",
    "url": "https://www.clinicaltrialsarena.com/news/eli-lillys-oral-glp-1ra-gains-fourth-phase-iii-type-2-diabetes-win/",
    "source": "Clinical Trials Arena",
    "provider": "yfinance",
    "raw": {
      "id": "7b9439f9-2844-35ae-9971-44f1d196d924",
      "content": {
        "id": "7b9439f9-2844-35ae-9971-44f1d196d924",
        "contentType": "STORY",
        "title": "Eli Lilly’s oral GLP-1RA gains fourth Phase III type 2 diabetes win",
        "description": "",
        "summary": "The company has announced positive data from the ACHIEVE-2 and ACHIEVE-5 trials, with both meeting all their primary and key secondary endpoints.",
        "pubDate": "2025-10-16T11:01:31Z",
        "displayTime": "2025-10-16T11:01:31Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/clinical_trials_arena_396/2ec21a6bd88db3d21e1e6dbe5d75ecc6",
          "originalWidth": 1000,
          "originalHeight": 666,
          "caption": "Lilly is continuing with its goal of submitting for approval of orforglipron in obesity by the end of 2025",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/X4xVdM19ob3rijozKIjqFw--~B/aD02NjY7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/2ec21a6bd88db3d21e1e6dbe5d75ecc6.cf.webp",
              "width": 1000,
              "height": 666,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uCGWaT041D5jKu8nozPFYA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/clinical_trials_arena_396/2ec21a6bd88db3d21e1e6dbe5d75ecc6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Clinical Trials Arena",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.clinicaltrialsarena.com/news/eli-lillys-oral-glp-1ra-gains-fourth-phase-iii-type-2-diabetes-win/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-oral-glp-1ra-110131955.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AZN.L"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-16T05:34:34+00:00",
    "headline": "Erste Group Upgrades Eli Lilly (LLY) to Buy Following Strong First-Half Results",
    "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 11 Defensive Healthcare Dividend Stocks to Buy Now. Eli Lilly and Company (NYSE:LLY) is an American multinational pharmaceutical company. The stock has surged by over 4% since the start of 2025. E​rste Group raised its ratin‍g on Eli Lilly and Company (NYSE:LLY) from Ho⁠ld‍ to Buy […]",
    "url": "https://finance.yahoo.com/news/erste-group-upgrades-eli-lilly-053434533.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "95826a8a-e3ef-3649-84ef-5d8779fc4e0c",
      "content": {
        "id": "95826a8a-e3ef-3649-84ef-5d8779fc4e0c",
        "contentType": "STORY",
        "title": "Erste Group Upgrades Eli Lilly (LLY) to Buy Following Strong First-Half Results",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 11 Defensive Healthcare Dividend Stocks to Buy Now. Eli Lilly and Company (NYSE:LLY) is an American multinational pharmaceutical company. The stock has surged by over 4% since the start of 2025. E​rste Group raised its ratin‍g on Eli Lilly and Company (NYSE:LLY) from Ho⁠ld‍ to Buy […]",
        "pubDate": "2025-10-16T05:34:34Z",
        "displayTime": "2025-10-16T05:34:34Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Erste Group Upgrades Eli Lilly (LLY) to Buy Following Strong First-Half Results",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6aY42asq7dEA24eM0JX3IQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8359URliL1_uJRGx4OlSUg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/erste-group-upgrades-eli-lilly-053434533.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/erste-group-upgrades-eli-lilly-053434533.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "EBS.VI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]